Phibro Animal Health (PAHC) Stock Still Looks Reasonable Following Its 264% Run

Phibro Animal Health has had a sharp reset in recent weeks. Yet over the past few years the stock has still delivered a very large gain. That mix of a steep pullback and a stronger longer run raises a simple question for investors who follow Phibro Animal Health: whether the current share price lines up with what its earnings can support.

• Phibro Animal Health has surged about 264% over the last 3 years, which puts a lot of weight on the idea that its profits can justify where the stock trades today.
• Recent news highlighting higher revenue, solid profitability and reaffirmed expectations for future performance can influence how durable investors think the company’s earnings power will be.
• Your read on Phibro Animal Health is one view; the desks covering it have another. See what analysts think Phibro Animal Health's shares could be worth.

The stock's next move may depend on whether Phibro Animal Health's current valuation looks sensible once you line it up against its earnings profile.

If you want to explore the same earnings question that Phibro Animal Health now faces across a wider watchlist, run the numbers against 39 high quality undervalued stocks.

Does Phibro Animal Health Look Undervalued on Earnings?

The P/E ratio fits Phibro Animal Health because investors are closely watching the earnings profile that underpins the recent share price move. On this measure, the stock trades at about 13.0x earnings, which is below both the Pharmaceuticals sector average of roughly 15.8x and a peer group closer to 17.4x. Compared with these reference points, the market is putting a lower earnings multiple on Phibro Animal Health than on many similar businesses.

The fair-value framework points to a higher P/E as a better match for Phibro Animal Health given its mix of growth prospects, profitability and risk, so the current 13.0x sits on the cheaper side of that range. Because the latest quarterly update reaffirmed guidance while keeping earnings expectations intact, this lower multiple indicates that the recent pullback has not fully repriced the stock in line with those forecasts. Explore the numbers behind Phibro Animal Health's P/E valuation.

The Phibro Animal Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Phibro Animal Health pick up where this valuation puzzle leaves off by explaining which paths for growth, margins and earnings would need to occur for the stock to end up worth materially more or less than today’s price. Each narrative links its valuation outcome to a specific view on how Phibro Animal Health's expansion, profitability and risks might develop, giving you a concrete story you can revisit as fresh information becomes available.

One of the top community narratives on Phibro Animal Health: 30% undervalued

"The current valuation implies the share price does not fully reflect the record fiscal 2026 results, expected EBITDA contributions from efficiency programs…"

Discover why this Narrative puts Phibro Animal Health at 30% undervalued.

Before making a call on Phibro Animal Health, there is one more piece to check

Price and earnings only tell part of the story for Phibro Animal Health. The people setting priorities, allocating capital and rewarding themselves can tilt the whole risk profile. See who runs Phibro Animal Health and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com